Abiraterone
The serum concentration of Dapagliflozin can be increased when it is combined with Abiraterone.
Acebutolol
The risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.
Acetohexamide
Dapagliflozin may increase the hypoglycemic activities of Acetohexamide.
Advertisement
Acetyl salicylate
Acetylsalicylic acid may increase the hypoglycemic activities of Dapagliflozin.
Acetyl Sulfisoxazole
The metabolism of Dapagliflozin can be decreased when combined with Acetyl sulfisoxazole.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.
Advertisement
Aliskiren
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.
Aloxiprin
Aloxiprin may increase the hypoglycemic activities of Dapagliflozin.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Dapagliflozin.
Advertisement
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Dapagliflozin.
Amiloride
The risk or severity of adverse effects can be increased when Amiloride is combined with Dapagliflozin.
Aminosalicylic Acid
Aminosalicylic Acid may increase the hypoglycemic activities of Dapagliflozin.
Amiodarone
The metabolism of Dapagliflozin can be decreased when combined with Amiodarone.
Amlodipine
The risk or severity of adverse effects can be increased when Amlodipine is combined with Dapagliflozin.
Amobarbital
Amobarbital may increase the hypotensive activities of Dapagliflozin.
Amphetamine
Amphetamine may increase the hypoglycemic activities of Dapagliflozin.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dapagliflozin.
Apalutamide
The serum concentration of Dapagliflozin can be decreased when it is combined with Apalutamide.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.
Apraclonidine
The risk or severity of adverse effects can be increased when Apraclonidine is combined with Dapagliflozin.
Aprepitant
The serum concentration of Dapagliflozin can be increased when it is combined with Aprepitant.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Dapagliflozin.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dapagliflozin.
Artemether
The metabolism of Dapagliflozin can be decreased when combined with Artemether.
Aspirin
Acetylsalicylic acid may increase the hypoglycemic activities of Dapagliflozin.
Atazanavir
The metabolism of Dapagliflozin can be decreased when combined with Atazanavir.
Atenolol
The risk or severity of adverse effects can be increased when Atenolol is combined with Dapagliflozin.
Atomoxetine
The metabolism of Dapagliflozin can be decreased when combined with Atomoxetine.
Azilsartan
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.
Azithromycin
The metabolism of Dapagliflozin can be decreased when combined with Azithromycin.
Balsalazide
Balsalazide may increase the hypoglycemic activities of Dapagliflozin.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Dapagliflozin.
Barbital
Barbital may increase the hypotensive activities of Dapagliflozin.
Benazepril
The risk or severity of adverse effects can be increased when Benazepril is combined with Dapagliflozin.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dapagliflozin.
Bepridil
The risk or severity of adverse effects can be increased when Bepridil is combined with Dapagliflozin.
Betaxolol
The metabolism of Dapagliflozin can be decreased when combined with Betaxolol.
Bisoprolol
The risk or severity of adverse effects can be increased when Bisoprolol is combined with Dapagliflozin.
Boceprevir
The metabolism of Dapagliflozin can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Dapagliflozin can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Dapagliflozin can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Dapagliflozin can be decreased when it is combined with Bosentan.
Bretylium
The risk or severity of adverse effects can be increased when Bretylium is combined with Dapagliflozin.
Brimonidine
The risk or severity of adverse effects can be increased when Brimonidine is combined with Dapagliflozin.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapagliflozin.
Bumetanide
The risk or severity of adverse effects can be increased when Bumetanide is combined with Dapagliflozin.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapagliflozin.
Bupropion
The metabolism of Dapagliflozin can be decreased when combined with Bupropion.
Caffeine
The metabolism of Dapagliflozin can be decreased when combined with Caffeine.
Canagliflozin
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Canagliflozin.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dapagliflozin.
Capecitabine
The metabolism of Dapagliflozin can be decreased when combined with Capecitabine.
Captopril
The risk or severity of adverse effects can be increased when Captopril is combined with Dapagliflozin.
Carbamazepine
The metabolism of Dapagliflozin can be increased when combined with Carbamazepine.
Carteolol
The risk or severity of adverse effects can be increased when Carteolol is combined with Dapagliflozin.
Carvedilol
The risk or severity of adverse effects can be increased when Carvedilol is combined with Dapagliflozin.
Celecoxib
The metabolism of Dapagliflozin can be decreased when combined with Celecoxib.
Ceritinib
The serum concentration of Dapagliflozin can be increased when it is combined with Ceritinib.
Chloroquine
The metabolism of Dapagliflozin can be decreased when combined with Chloroquine.
Chlorothiazide
The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin.
Chlorpromazine
The metabolism of Dapagliflozin can be decreased when combined with Chlorpromazine.
Chlorpropamide
Dapagliflozin may increase the hypoglycemic activities of Chlorpropamide.
Chlorthalidone
The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dapagliflozin.
Cholecalciferol
The metabolism of Dapagliflozin can be decreased when combined with Cholecalciferol.
Cilazapril
The risk or severity of adverse effects can be increased when Cilazapril is combined with Dapagliflozin.
Cimetidine
The metabolism of Dapagliflozin can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Dapagliflozin can be decreased when combined with Cinacalcet.
Cinoxacin
Cinoxacin may increase the hypoglycemic activities of Dapagliflozin.
Ciprofloxacin
Ciprofloxacin may increase the hypoglycemic activities of Dapagliflozin.
Citalopram
The metabolism of Dapagliflozin can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Dapagliflozin can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Dapagliflozin can be decreased when combined with Clemastine.
Clevidipine
The risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.
Clobazam
The metabolism of Dapagliflozin can be decreased when combined with Clobazam.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Dapagliflozin.
Clomipramine
The metabolism of Dapagliflozin can be decreased when combined with Clomipramine.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.
Clotrimazole
The metabolism of Dapagliflozin can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Dapagliflozin can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Dapagliflozin can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Dapagliflozin can be decreased when combined with Cocaine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Dapagliflozin.
Crisaborole
The metabolism of Dapagliflozin can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Dapagliflozin can be decreased when combined with Crizotinib.
Curcumin
The metabolism of Dapagliflozin can be decreased when combined with Curcumin.
Cyclosporine
The metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.
Cyproterone Acetate
The serum concentration of Dapagliflozin can be decreased when it is combined with Cyproterone acetate.
Dabrafenib
The serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.
Darifenacin
The metabolism of Dapagliflozin can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Dapagliflozin can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Dapagliflozin can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Dapagliflozin can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Dapagliflozin.
Desipramine
The metabolism of Dapagliflozin can be decreased when combined with Desipramine.
Desvenlafaxine
Desvenlafaxine may increase the hypoglycemic activities of Dapagliflozin.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapagliflozin.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Dapagliflozin.
Diflunisal
Diflunisal may increase the hypoglycemic activities of Dapagliflozin.
Dihydroergotamine
The metabolism of Dapagliflozin can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Dapagliflozin can be decreased when combined with Diltiazem.
Dinutuximab
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.
Diphenhydramine
The metabolism of Dapagliflozin can be decreased when combined with Diphenhydramine.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.
Dothiepin
The metabolism of Dapagliflozin can be decreased when combined with Dosulepin.
Doxazosin
The risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.
Doxycycline
The metabolism of Dapagliflozin can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Dapagliflozin can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Dapagliflozin can be decreased when combined with Dronedarone.
Duloxetine
Dapagliflozin may increase the orthostatic hypotensive activities of Duloxetine.
Efavirenz
The metabolism of Dapagliflozin can be decreased when combined with Efavirenz.
Eliglustat
The metabolism of Dapagliflozin can be decreased when combined with Eliglustat.
Empagliflozin
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin.
Enalapril
The risk or severity of adverse effects can be increased when Enalapril is combined with Dapagliflozin.
Enalaprilat
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dapagliflozin.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dapagliflozin.
Enoxacin
Enoxacin may increase the hypoglycemic activities of Dapagliflozin.
Enzalutamide
The serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide.
Eplerenone
The risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dapagliflozin.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.
Erythromycin
The metabolism of Dapagliflozin can be decreased when combined with Erythromycin.
Escitalopram
Escitalopram may increase the hypoglycemic activities of Dapagliflozin.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.
Ethacrynate
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dapagliflozin.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dapagliflozin.
Etravirine
The metabolism of Dapagliflozin can be decreased when combined with Etravirine.
Felodipine
The risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Dapagliflozin.
Fleroxacin
Fleroxacin may increase the hypoglycemic activities of Dapagliflozin.
Floxuridine
The metabolism of Dapagliflozin can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Dapagliflozin can be decreased when combined with Fluconazole.
Flumequine
Flumequine may increase the hypoglycemic activities of Dapagliflozin.
Fluorouracil
The metabolism of Dapagliflozin can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Dapagliflozin can be decreased when combined with Fluoxetine.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Dapagliflozin.
Fluvastatin
The metabolism of Dapagliflozin can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Dapagliflozin can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Dapagliflozin can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Dapagliflozin can be increased when it is combined with Fosaprepitant.
Fosinopril
The risk or severity of adverse effects can be increased when Fosinopril is combined with Dapagliflozin.
Fosphenytoin
The metabolism of Dapagliflozin can be increased when combined with Fosphenytoin.
Furazolidone
Furazolidone may increase the hypoglycemic activities of Dapagliflozin.
Furosemide
The risk or severity of adverse effects can be increased when Furosemide is combined with Dapagliflozin.
Fusidate
The serum concentration of Dapagliflozin can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Dapagliflozin can be increased when it is combined with Fusidic Acid.
Gatifloxacin
Gatifloxacin may increase the hypoglycemic activities of Dapagliflozin.
Gatifloxacin Anhydrous
Gatifloxacin may increase the hypoglycemic activities of Dapagliflozin.
Gemfibrozil
The metabolism of Dapagliflozin can be decreased when combined with Gemfibrozil.
Gemifloxacin
Gemifloxacin may increase the hypoglycemic activities of Dapagliflozin.
Gemifloxacin Mesylate
Gemifloxacin may increase the hypoglycemic activities of Dapagliflozin.
Glibornuride
Dapagliflozin may increase the hypoglycemic activities of Glibornuride.
Gliclazide
Dapagliflozin may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Dapagliflozin may increase the hypoglycemic activities of Glimepiride.
Glipizide
Dapagliflozin may increase the hypoglycemic activities of Glipizide.
Gliquidone
Dapagliflozin may increase the hypoglycemic activities of Gliquidone.
Glyburide
Dapagliflozin may increase the hypoglycemic activities of Glyburide.
Grepafloxacin
Grepafloxacin may increase the hypoglycemic activities of Dapagliflozin.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.
Haloperidol
The metabolism of Dapagliflozin can be decreased when combined with Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Dapagliflozin.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Dapagliflozin.
Hydralazine
The risk or severity of adverse effects can be increased when Hydralazine is combined with Dapagliflozin.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dapagliflozin.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dapagliflozin.
Hypoxis hemerocallidea root extract
The serum concentration of Dapagliflozin can be decreased when it is combined with St. John's Wort.
Idelalisib
The metabolism of Dapagliflozin can be decreased when combined with Idelalisib.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Dapagliflozin.
Imatinib
The metabolism of Dapagliflozin can be decreased when combined with Imatinib.
Imidapril
The risk or severity of adverse effects can be increased when Imidapril is combined with Dapagliflozin.
Imipramine
The metabolism of Dapagliflozin can be decreased when combined with Imipramine.
Indapamide
The risk or severity of adverse effects can be increased when Indapamide is combined with Dapagliflozin.
Indinavir
The metabolism of Dapagliflozin can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Dapagliflozin can be decreased when combined with Indinavir.
Indoramin
The risk or severity of adverse effects can be increased when Indoramin is combined with Dapagliflozin.
insulin human, rDNA origin
Dapagliflozin may increase the hypoglycemic activities of Insulin Human.
Insulin, Pork
Dapagliflozin may increase the hypoglycemic activities of Insulin Pork.
Insulin, Regular, Pork
Dapagliflozin may increase the hypoglycemic activities of Insulin Pork.
Iproniazid
Iproniazid may increase the hypoglycemic activities of Dapagliflozin.
Irbesartan
The metabolism of Dapagliflozin can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Dapagliflozin can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Dapagliflozin can be decreased when combined with Isavuconazonium.
Isocarboxazid
Isocarboxazid may increase the hypoglycemic activities of Dapagliflozin.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Dapagliflozin.
Isoniazid
The metabolism of Dapagliflozin can be decreased when combined with Isoniazid.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dapagliflozin.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dapagliflozin.
Isoxsuprine
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Isoxsuprine.
Isradipine
The metabolism of Dapagliflozin can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Dapagliflozin can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Dapagliflozin can be increased when it is combined with Ivacaftor.
Ketoconazole
The metabolism of Dapagliflozin can be decreased when combined with Ketoconazole.
Labetalol
The risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.
Lacidipine
Dapagliflozin may increase the hypotensive activities of Lacidipine.
Leflunomide
The metabolism of Dapagliflozin can be decreased when combined with Leflunomide.
Lercanidipine
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Dapagliflozin.
Levobunolol
The risk or severity of adverse effects can be increased when Levobunolol is combined with Dapagliflozin.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dapagliflozin.
Levodopa
Dapagliflozin may increase the orthostatic hypotensive activities of Levodopa.
Levofloxacin
Levofloxacin may increase the hypoglycemic activities of Dapagliflozin.
Levofloxacin Anhydrous
Levofloxacin may increase the hypoglycemic activities of Dapagliflozin.
Levomilnacipran
Levomilnacipran may increase the hypoglycemic activities of Dapagliflozin.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Dapagliflozin.
Lidocaine
The metabolism of Dapagliflozin can be decreased when combined with Lidocaine.
Lisinopril
The risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Dapagliflozin.
Lomefloxacin
Lomefloxacin may increase the hypoglycemic activities of Dapagliflozin.
Lopinavir
The metabolism of Dapagliflozin can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Dapagliflozin can be decreased when combined with Lorcaserin.
Losartan
The metabolism of Dapagliflozin can be decreased when combined with Losartan.
Lovastatin
The metabolism of Dapagliflozin can be decreased when combined with Lovastatin.
Luliconazole
The serum concentration of Dapagliflozin can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Dapagliflozin can be decreased when it is combined with Lumacaftor.
Lumefantrine
The metabolism of Dapagliflozin can be decreased when combined with Lumefantrine.
Manidipine
The metabolism of Dapagliflozin can be decreased when combined with Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Mannitol is combined with Dapagliflozin.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Dapagliflozin.
Mepirodipine
The risk or severity of adverse effects can be increased when Barnidipine is combined with Dapagliflozin.
Mesalamine
Mesalazine may increase the hypoglycemic activities of Dapagliflozin.
Mesterolone
Mesterolone may increase the hypoglycemic activities of Dapagliflozin.
Methadone
The metabolism of Dapagliflozin can be decreased when combined with Methadone.
Methazolamide
The risk or severity of adverse effects can be increased when Methazolamide is combined with Dapagliflozin.
Methohexital
Methohexital may increase the hypotensive activities of Dapagliflozin.
Methotrimeprazine
The metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dapagliflozin.
Methyl Salicylate
Methyl salicylate may increase the hypoglycemic activities of Dapagliflozin.
Methyldopa
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.
Methylene blue
Methylene blue may increase the hypoglycemic activities of Dapagliflozin.
Methyltestosterone
Methyltestosterone may increase the hypoglycemic activities of Dapagliflozin.
Metipranolol
The risk or severity of adverse effects can be increased when Metipranolol is combined with Dapagliflozin.
Metolazone
The risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin.
Metoprolol
The metabolism of Dapagliflozin can be decreased when combined with Metoprolol.
Mexiletine
The metabolism of Dapagliflozin can be decreased when combined with Mexiletine.
Midostaurin
The metabolism of Dapagliflozin can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Dapagliflozin can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the hypoglycemic activities of Dapagliflozin.
Minaprine
Minaprine may increase the hypoglycemic activities of Dapagliflozin.
Minoxidil
The risk or severity of adverse effects can be increased when Minoxidil is combined with Dapagliflozin.
Mirabegron
The metabolism of Dapagliflozin can be decreased when combined with Mirabegron.
Mitotane
The serum concentration of Dapagliflozin can be decreased when it is combined with Mitotane.
Moclobemide
Moclobemide may increase the hypoglycemic activities of Dapagliflozin.
Moexipril
The risk or severity of adverse effects can be increased when Moexipril is combined with Dapagliflozin.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Dapagliflozin.
Moxifloxacin
Moxifloxacin may increase the hypoglycemic activities of Dapagliflozin.
Moxonidine
The risk or severity of adverse effects can be increased when Moxonidine is combined with Dapagliflozin.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Dapagliflozin.
Nadolol
The risk or severity of adverse effects can be increased when Nadolol is combined with Dapagliflozin.
Nalidixic Acid
Nalidixic Acid may increase the hypoglycemic activities of Dapagliflozin.
Nandrolone
Nandrolone may increase the hypoglycemic activities of Dapagliflozin.
Nandrolone Decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Dapagliflozin.
Nebivolol
The risk or severity of adverse effects can be increased when Nebivolol is combined with Dapagliflozin.
Nefazodone
The metabolism of Dapagliflozin can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Dapagliflozin can be decreased when combined with Nelfinavir.
Nesiritide
The risk or severity of adverse effects can be increased when Nesiritide is combined with Dapagliflozin.
Netupitant
The serum concentration of Dapagliflozin can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Dapagliflozin can be increased when combined with Nevirapine.
Nialamide
Nialamide may increase the hypoglycemic activities of Dapagliflozin.
Nicardipine
The metabolism of Dapagliflozin can be decreased when combined with Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Dapagliflozin.
Nicotine
The metabolism of Dapagliflozin can be decreased when combined with Nicotine.
Nicotine Polacrilex
The metabolism of Dapagliflozin can be decreased when combined with Nicotine.
Nifedipine
The risk or severity of adverse effects can be increased when Nifedipine is combined with Dapagliflozin.
Nilotinib
The metabolism of Dapagliflozin can be decreased when combined with Nilotinib.
Nilvadipine
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Dapagliflozin.
Nimodipine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Dapagliflozin.
Nisoldipine
The risk or severity of adverse effects can be increased when Nisoldipine is combined with Dapagliflozin.
Nitrendipine
The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dapagliflozin.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dapagliflozin.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.
Nitroprusside
The risk or severity of adverse effects can be increased when Nitroprusside is combined with Dapagliflozin.
Norfloxacin
Norfloxacin may increase the hypoglycemic activities of Dapagliflozin.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dapagliflozin.
Ofloxacin
Ofloxacin may increase the hypoglycemic activities of Dapagliflozin.
Olaparib
The metabolism of Dapagliflozin can be decreased when combined with Olaparib.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.
Olsalazine
Olsalazine may increase the hypoglycemic activities of Dapagliflozin.
Omeprazole
The metabolism of Dapagliflozin can be decreased when combined with Omeprazole.
Osimertinib
The serum concentration of Dapagliflozin can be increased when it is combined with Osimertinib.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Dapagliflozin.
Oxprenolol
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Dapagliflozin.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Dapagliflozin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dapagliflozin.
Palbociclib
The serum concentration of Dapagliflozin can be increased when it is combined with Palbociclib.
Panobinostat
The serum concentration of Dapagliflozin can be increased when it is combined with Panobinostat.
Papaverine
The risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Dapagliflozin.
Pargyline
Pargyline may increase the hypoglycemic activities of Dapagliflozin.
Paroxetine
The metabolism of Dapagliflozin can be decreased when combined with Paroxetine.
Pefloxacin
Pefloxacin may increase the hypoglycemic activities of Dapagliflozin.
Peginterferon Alfa-2b
The serum concentration of Dapagliflozin can be decreased when it is combined with Peginterferon alfa-2b.
Pegvisomant
Pegvisomant may increase the hypoglycemic activities of Dapagliflozin.
Penbutolol
The risk or severity of adverse effects can be increased when Penbutolol is combined with Dapagliflozin.
Pentobarbital
The metabolism of Dapagliflozin can be increased when combined with Pentobarbital.
Perindopril
The risk or severity of adverse effects can be increased when Perindopril is combined with Dapagliflozin.
Phenelzine
Phenelzine may increase the hypoglycemic activities of Dapagliflozin.
Phenobarbital
The metabolism of Dapagliflozin can be increased when combined with Phenobarbital.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dapagliflozin.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Dapagliflozin.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Phentolamine is combined with Dapagliflozin.
Phenytoin
The metabolism of Dapagliflozin can be increased when combined with Phenytoin.
Pindolol
The risk or severity of adverse effects can be increased when Pindolol is combined with Dapagliflozin.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Dapagliflozin.
Posaconazole
The metabolism of Dapagliflozin can be decreased when combined with Posaconazole.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Dapagliflozin.
Prazosin
The risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.
Primidone
The metabolism of Dapagliflozin can be increased when combined with Primidone.
Procaine
Procaine may increase the hypoglycemic activities of Dapagliflozin.
Procarbazine
Procarbazine may increase the hypoglycemic activities of Dapagliflozin.
Promazine
The metabolism of Dapagliflozin can be decreased when combined with Promazine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Dapagliflozin.
Propranolol
The risk or severity of adverse effects can be increased when Propranolol is combined with Dapagliflozin.
Pyrimethamine
The metabolism of Dapagliflozin can be decreased when combined with Pyrimethamine.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.
Quinapril
The risk or severity of adverse effects can be increased when Quinapril is combined with Dapagliflozin.
Quinidine
The metabolism of Dapagliflozin can be decreased when combined with Quinidine.
Quinine
The metabolism of Dapagliflozin can be decreased when combined with Quinine.
Ramipril
The risk or severity of adverse effects can be increased when Ramipril is combined with Dapagliflozin.
Ranolazine
The serum concentration of Dapagliflozin can be increased when it is combined with Ranolazine.
Rasagiline
Rasagiline may increase the hypoglycemic activities of Dapagliflozin.
Regular Insulin, Human
Dapagliflozin may increase the hypoglycemic activities of Insulin Human.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Dapagliflozin.
Rescinnamine
The risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Rescinnamine.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Dapagliflozin.
Rifabutin
The metabolism of Dapagliflozin can be increased when combined with Rifabutin.
Rifampin
The metabolism of Dapagliflozin can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Dapagliflozin can be increased when combined with Rifapentine.
Riociguat
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Riociguat.
Risperidone
Dapagliflozin may increase the hypotensive activities of Risperidone.
Ritonavir
The metabolism of Dapagliflozin can be decreased when combined with Ritonavir.
Rolapitant
The metabolism of Dapagliflozin can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Dapagliflozin can be decreased when combined with Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapagliflozin.
Rosoxacin
Rosoxacin may increase the hypoglycemic activities of Dapagliflozin.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Dapagliflozin.
Rucaparib
The metabolism of Dapagliflozin can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Dapagliflozin.
Salicylic Acid
Salicylic acid may increase the hypoglycemic activities of Dapagliflozin.
Saquinavir
The metabolism of Dapagliflozin can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Dapagliflozin can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sarilumab.
Secobarbital
The metabolism of Dapagliflozin can be increased when combined with Secobarbital.
Selegiline
Selegiline may increase the hypoglycemic activities of Dapagliflozin.
Sertraline
The metabolism of Dapagliflozin can be decreased when combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapagliflozin.
Sildenafil
The metabolism of Dapagliflozin can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Dapagliflozin can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Dapagliflozin can be increased when it is combined with Simeprevir.
Sorafenib
The metabolism of Dapagliflozin can be decreased when combined with Sorafenib.
Sotalol
The risk or severity of adverse effects can be increased when Sotalol is combined with Dapagliflozin.
Sparfloxacin
Sparfloxacin may increase the hypoglycemic activities of Dapagliflozin.
Spirapril
The risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.
ST. JOHN'S WORT EXTRACT
The serum concentration of Dapagliflozin can be decreased when it is combined with St. John's Wort.
Stanozolol
Stanozolol may increase the hypoglycemic activities of Dapagliflozin.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Dapagliflozin.
Sulfadiazine
The metabolism of Dapagliflozin can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Dapagliflozin can be decreased when combined with Sulfamethoxazole.
Sulfisoxazole
The metabolism of Dapagliflozin can be decreased when combined with Sulfisoxazole.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Dapagliflozin.
Telaprevir
The metabolism of Dapagliflozin can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Dapagliflozin can be decreased when combined with Telithromycin.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.
Temafloxacin
Temafloxacin may increase the hypoglycemic activities of Dapagliflozin.
Tenofovir Disoproxil
The metabolism of Dapagliflozin can be decreased when combined with Tenofovir disoproxil.
Terazosin
The risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.
Terbinafine
The metabolism of Dapagliflozin can be decreased when combined with Terbinafine.
Teriflunomide
The serum concentration of Dapagliflozin can be decreased when it is combined with Teriflunomide.
Testosterone
Testosterone may increase the hypoglycemic activities of Dapagliflozin.
Testosterone Cypionate
Testosterone cypionate may increase the hypoglycemic activities of Dapagliflozin.
Testosterone Enanthate
Testosterone enanthate may increase the hypoglycemic activities of Dapagliflozin.
Testosterone Propionate
Testosterone propionate may increase the hypoglycemic activities of Dapagliflozin.
Testosterone Undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Dapagliflozin.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Dapagliflozin.
Theophylline
The metabolism of Dapagliflozin can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Dapagliflozin can be decreased when combined with Theophylline.
Thiamylal
Thiamylal may increase the hypotensive activities of Dapagliflozin.
Thiopental
Thiopental may increase the hypotensive activities of Dapagliflozin.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Dapagliflozin.
Thioridazine
The metabolism of Dapagliflozin can be decreased when combined with Thioridazine.
Ticagrelor
The metabolism of Dapagliflozin can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Dapagliflozin can be decreased when combined with Ticlopidine.
Timolol
The risk or severity of adverse effects can be increased when Timolol is combined with Dapagliflozin.
Timolol Anhydrous
The risk or severity of adverse effects can be increased when Timolol is combined with Dapagliflozin.
Tipranavir
The metabolism of Dapagliflozin can be decreased when combined with Tipranavir.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.
Tocilizumab
The serum concentration of Dapagliflozin can be decreased when it is combined with Tocilizumab.
Tolazamide
Dapagliflozin may increase the hypoglycemic activities of Tolazamide.
Tolazoline
The risk or severity of adverse effects can be increased when Tolazoline is combined with Dapagliflozin.
Tolbutamide
The metabolism of Dapagliflozin can be decreased when combined with Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Dapagliflozin.
Toloxatone
Toloxatone may increase the hypoglycemic activities of Dapagliflozin.
Torsemide
The risk or severity of adverse effects can be increased when Torasemide is combined with Dapagliflozin.
Trandolapril
The risk or severity of adverse effects can be increased when Trandolapril is combined with Dapagliflozin.
Tranylcypromine
The metabolism of Dapagliflozin can be decreased when combined with Tranylcypromine.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Dapagliflozin.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.
Trimethoprim
The metabolism of Dapagliflozin can be decreased when combined with Trimethoprim.
Trolamine Salicylate
Trolamine salicylate may increase the hypoglycemic activities of Dapagliflozin.
Trovafloxacin
Trovafloxacin may increase the hypoglycemic activities of Dapagliflozin.
Valproate
The metabolism of Dapagliflozin can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Dapagliflozin can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Dapagliflozin can be decreased when combined with Valsartan.
Vemurafenib
The serum concentration of Dapagliflozin can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Dapagliflozin can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Dapagliflozin can be decreased when combined with Verapamil.
Voriconazole
The metabolism of Dapagliflozin can be decreased when combined with Voriconazole.
Zafirlukast
The metabolism of Dapagliflozin can be decreased when combined with Zafirlukast.
Ziprasidone
The metabolism of Dapagliflozin can be decreased when combined with Ziprasidone.
Zofenopril
The risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Zofenopril.
